

### Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-39. (cancelled)

40. (currently amended): A protein of ~~approximately~~ 17 kDa as determined by SDS PAGE encoded by one of SEQ ID Nos ~~1, 3, or 5~~ NO 1, 3, 5 and sequences having similarity to SEQ ID NO 1, 3 and 5 that do not alter one of the immunogenicity and function of said protein.

41. (cancelled)

42. (currently amended): The ~~approximately 17 kDa protein of claim 40, encompassing amino acid substitutions, additions and deletions that do not alter one of the immunogenicity and the function of said protein~~ protein of claim 40, wherein said protein is encoded by one of SEQ ID NO 1, 3 and 5.

43. (currently amended): A ~~protein of approximately 17 kDa~~ protein ranging from 15.5 to 17.7 kDa as determined by SDS PAGE wherein said protein is immunoreactive with anti-*P. salmonis* serum.

44-49. (cancelled)

50. (new): A protein of 17 kDa as determined by SDS PAGE comprised of the amino acid sequence of one of SEQ ID NO 2, 4, 6 and variants of SEQ ID NO 2, 4 and 6 that do not alter one of the immunogenicity or function of said protein.
  51. (new): The protein of claim 50 wherein the amino acid sequence is selected from one of SEQ ID NO 2, 4 and 6.
  52. (new): The protein of claim 50 wherein the protein or variants thereof are fused to at least one other protein or protein fragment either at the N or C terminus or both.
  53. (new): The protein of claim 52 wherein those proteins or protein fragments are lymphocyte T cell epitopes or lymphocyte T cell epitopes and lymphocyte B cell epitopes.
  54. (new): The protein of claim 52 wherein the protein or variants thereof are post-translationally modified into a lipoprotein.
  55. (new): The protein of claim 52 wherein the lymphocyte T cell epitopes are highly immunogenic promiscuous T cell epitopes.
-